Critical Path Institute
The agreement is part of a larger effort by the company to apply its Signabody affinity reagents to toxicity biomarker work and other areas of drug development.
Critical Path Institute, TGen Partner on Tuberculosis Sequencing Project
The partners aim to sequence thousands of tuberculosis bacteria isolates as part of a broader effort to develop personalized treatments for the disease.
Consortium Seeks to Provide Centralized Access to Global TB Data for Research, Dx Development
Premium
The database of genotype, phenotype, and clinical data from multi-drug resistant TB cases may support improved diagnostic development and clinical decision making.
The data repository of tuberculosis drug susceptibility will spur diagnostic assay development; access will be open to partner firms in one year.
Certara, C-Path Partner on Testing Models for Tuberculosis Drugs
NEW YORK (GenomeWeb News) – Certara said this week that it is working with the Critical Path Institute, C-Path, to create a physiologically-based pharmacokinetic model of the human lung using Certara's Simcyp Population-based simulator software that will be used to test new tuberculosis drugs.
Apr 20, 2012
Feb 1, 2012
Dec 20, 2011
Critical Path, Hamner Institutes Ink Biomarker Pact
Apr 15, 2011
Movers & Shakers: Apr 15, 2011
Premium
Feb 23, 2011